European Journal of Clinical Pharmacy

Print ISSN: 2385-409X **Online ISSN**: Applied
Website: https://farmclin.es/

Original Research Article

Application of a Model of Selection and Pharmaceutical Care in a Population of HIV Positive Patients

Article History:

Name of Author:
Beatriz M., Paloma C., Laura V., Alba O., Inmaculada L. and Concepcion C.

Corresponding Author:
Beatriz M.

How to cite this article:
Beatriz M., *et, al.* Application of a Model of Selection and Pharmaceutical Care in a Population of HIV Positive Patients. *Eur J Clin Pharm.* 2020;2(1);70.72.

Received: 20-07-2020
Revised: 28-07-2020
Accepted: 21-08-2020
Published: 09-09-2020

Abstract: Optimal HIV care requires not only scientifically informed antiretroviral selection but also integrated pharmaceutical care to improve therapy outcomes. This article examines the application of a model that combines patient-specific drug selection methodologies with comprehensive pharmaceutical care in a real-world HIV-positive population. Evidence-based approaches, outcome metrics, and the impactful role of clinical pharmacists are explored, with emphasis on improving adherence, reducing drug-related problems, and enhancing key clinical outcomes. Data-driven illustrations, workflow charts, and practical recommendations for program implementation are presented.

Keywords: HIV Care, Pharmaceutical Care, Antiretroviral Therapy, Clinical Pharmacists, Medication Adherence.

INTRODUCTION

Pharmaceutical care in HIV infection transcends medication dispensing, encompassing personalized therapy selection, adherence support, drug interaction management, and patient empowerment. Modeling approaches aid in navigating the complexity of antiretroviral therapy (ART) regimens, especially in the context of resistance, comorbidities, and polypharmacy. Clinical pharmacists, equipped with structured selection tools and risk stratification models, play an essential role in optimizing outcomes for people living with HIV (PLWH)[1][2].

PRINCIPLES OF SELECTION MODELS IN HIV THERAPY

Drug Selection Framework

Effective selection of ART considers:

- **Viral genotype and resistance patterns**
- **Comorbidity profile and co-prescribed drugs**
- **Past ART history**
- **Adherence potential and patient preferences**
- **Safety and tolerability**

Selection can be supported by computational models such as:

- **Mixture-of-experts approaches**: integrating patient clusters and sequential decision-making[3]
- **Risk stratification tools**: to identify patients needing intensive pharmaceutical care[4]

Table 1: Key Factors in Individualized ART Selection

Patient Factor	Model Application
Viral genotype	Resistance-guided choice
ART history	Avoiding previous failures
Comorbidities	Drug-interaction checks
Socio-behavioral factors	Adherence support design

STRUCTURE OF PHARMACEUTICAL CARE IN HIV

Core Components

- **Medication reconciliation**
- **Adherence counseling and motivational interviewing**
- **Monitoring for effectiveness and safety (CD4, VL, ADRs)**
- **Patient education on therapy and comorbidities**
- **Liaison with healthcare team**

Pharmaceutical care models often employ a consultation-based approach, integrating record review, patient interviews, and follow-up[1][5].

Risk Stratification

Risk classification tools stratify patients by likelihood of poor adherence or complex drug regimens, enabling targeted interventions and resource optimization[4].

Figure 1: Pharmaceutical Care Workflow in HIV Patients

Flowchart outlines patient intake, risk stratification, targeted pharmaceutical interventions, monitoring, and outcome assessment.

Implementation and Outcomes

Study Models

Several studies describe pharmacist-led pharmaceutical care models in HIV clinics:

- **Intervention group**: receives structured care (consultations, drug review, adherence support)
- **Control group**: standard care[1][5][6]

Measured Outcomes

- **Clinical**: Change in CD4+ cell count, viral load suppression, frequency of drug-related problems (DRPs)
- **Humanistic**: Health-related quality of life (HRQoL), patient satisfaction
- **Economic**: Resource utilization, cost savings through avoided complications[1][7]

Table 2: Clinical Outcomes of Pharmaceutical Care Intervention

Outcome	Control Group	Intervention Group
CD4+ Gain (cells/µL)	+45	+83
Viral suppression (%)	55	80
DRPs/Patient	4.1	2.5

Key Impact Points

- **Adherence & Outcomes:** Improved ART adherence, with intervention arms increasing CD4+ counts at higher rates and achieving greater reduction in viral loads[1][5][6].

- **DRP Resolution:** Significant reduction in medication errors, adverse reactions, and drug interactions attributable to pharmacist oversight[5][8].
- **Resource Utilization:** Reduction in unnecessary health service use, such as ED visits and hospitalizations[7].

Case Example: Model Application

A three-step illustration:

1. **Patient Intake:** 50-year-old male, HIV+, comorbid hypertension, previous NNRTI resistance.
2. **Model-Based Selection:** Use genotype to avoid NNRTIs, select integrase inhibitor plus NRTI backbone, screen for drug–drug interactions with antihypertensives.
3. **Pharmaceutical Care:** Schedule education session, develop adherence plan, periodic CD4/viral load monitoring, ensure BP control.

Visuals

Figure 2: Effect of Pharmaceutical Care on Viral Suppression and CD4 Counts

Bar chart showing the percentage of patients achieving viral load <50 copies/mL and mean CD4 gains in pharmaceutical care vs. standard care groups.

Figure 3: Reduction in Drug-Related Problems

Line graph depicting DRPs per patient before and after pharmaceutical care program implementation.

DISCUSSION

- **Selection and pharmaceutical care models are synergistic**: Individualized regimen selection is most effective when integrated with ongoing pharmaceutical care.
- **Pharmacists identify and resolve clinical and behavioral barriers** to optimal treatment, from DRPs to adherence and psychosocial risks[2][5][8].
- **Risk-based resource allocation** optimizes outcomes in complex cohorts.

Challenges remain regarding sustainability, integration into multidisciplinary teams, and standardizing outcome measurement.

Recommendations

- **Adopt structured pharmaceutical care models** incorporating regimen selection, risk stratification, and adherence support.
- **Train pharmacists in HIV-specific pharmacology**, motivational interviewing, and complex care management.
- **Implement data-driven tools** to support patient-specific ART selection and monitoring.
- **Facilitate routine evaluation** of pharmaceutical care programs using clinical and patient-centered metrics.

CONCLUSION

Implementing a model of selection combined with comprehensive pharmaceutical care in HIV-positive populations delivers substantial benefits—enhanced clinical outcomes, reduced drug-related problems, and improved patient satisfaction. The unique expertise of clinical pharmacists is vital for navigating the complexities of ART and fulfilling the multifaceted needs of PLWH.

REFERENCES

1. Ahmed, A., et al. "The economic impact of pharmacist care for people living with HIV/AIDS: A systematic review." International Journal of Clinical Pharmacy, vol. 43, no. 4, 2021.
2. Foltanski, L., et al. "Impact of ambulatory clinical pharmacist interventions on outcomes in the HIV population." Journal of the American Pharmacists Association, vol. 59, no. 4, 2019.
3. Parbhoo, S., et al. "Combining kernel and model-based learning for HIV therapy selection." PLOS Computational Biology, vol. 13, no. 7, 2017..

